Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | PGR | P06401 | 4/20 | 0.80 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | TNF | P01375 | 1/20 | 0.72 |
| ▸ | IL6 | P05231 | 1/20 | 0.72 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.72 |
| ▸ | GLUL | P15104 | 1/20 | 0.72 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.72 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone Hemisuccinate SCHEMBL25138782 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL13026153 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL139689 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL12540510 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL16009511 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL3360749 | 0.99 | HIF1A (0.84) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL27639542 | 0.99 | HIF1A (0.84) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL7155955 | 0.99 | HIF1A (0.84) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| SCHEMBL16009510 | 0.97 | HIF1A (0.91) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| SCHEMBL16170220 | 0.93 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598506-A1 | USE OF LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSIONS FOR TREATING AND PREVENTING INFLAMMATIONS OF THE GASTROINTESTINAL TRACT | Eupraxia Pharmaceuticals Inc. (CA) | 2025-08-13 | — | — | EP | claimed |
| CN-119968199-A | Use of long-acting fluticasone propionate injection suspension for treating and preventing gastrointestinal tract inflammation | 优普顺药物公司 | 2025-05-09 | — | — | CN | claimed |
| WO-2024077017-A1 | USE OF LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSIONS FOR TREATING AND PREVENTING INFLAMMATIONS OF THE GASTROINTESTINAL TRACT | EUPRAXIA PHARMACEUTICALS INC. (CA) | 2024-04-11 | — | — | WO | claimed |
| CN-116396347-A | Preparation method of high-standard prednisolone succinate | 河南利华制药有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20220072010-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS (US) | 2022-03-10 | — | — | US | claimed |
| EP-3038660-B1 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | AIHOL CORP (US) | 2020-12-23 | — | — | EP | claimed |
| US-20180256599-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2018-09-13 | — | — | US | claimed |
| EP-1744683-B1 | APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE AGENTS | ALZA CORP (US) | 2016-03-16 | — | — | EP | claimed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | claimed |
| CN-100546656-C | A kind of kidney-targeted medicine vector reaches prodrug, method for making and the application with its formation | UNIV SICHUAN (CN) | 2009-10-07 | — | — | CN | claimed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | claimed |
| US-20070077286-A1 | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle | LTT BIO-PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | claimed |
| EP-1754712-A2 | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-02-21 | — | — | EP | claimed |
| CN-1879889-A | Kidney-targeted medicine vector and the formed prodrug, preparation method and uses | UNIV SICHUAN (CN) | 2006-12-20 | — | — | CN | claimed |
| CN-1861193-A | Kidney target precursor medicine, said prepn., its preparing method and application | UNIV SICHUAN (CN) | 2006-11-15 | — | — | CN | claimed |
| EP-1698329-A1 | DRUG-CONTAINING NANOPARTICLE, PROCESS FOR PRODUCING THE SAME AND PARENTERALLY ADMINISTERED PREPARATION FROM THE NANOPARTICLE | LTT Bio-Pharma Co., Ltd. (JP) | 2006-09-06 | — | — | EP | claimed |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-07-27 | — | — | US | claimed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | HIF1A 3432/4885LMNA 262/4885PGR 1652/4885 |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | HIF1A 3432/4885LMNA 262/4885PGR 1652/4885 |
| US-20220072010-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C2, NR3C1 | HIF1A 4810/4885LMNA 4389/4885PGR 1073/4885 |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | HIF1A 4786/4885LMNA 4428/4885PGR 1161/4885 |
| US-20180256599-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C2, NR3C1 | HIF1A 4810/4885LMNA 4389/4885PGR 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.